ORIC PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
ORIC PHARMACEUTICALS, INC. (ORIC) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of 4.01% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-02-23
- ORIC PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was 4.01%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month |
|---|---|
| 2025-12-31 | 4.01% 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |